2024 Australia-New Zealand Expert Consensus Statement on Cardiac Amyloidosis

Nicole K Bart; Diane Fatkin; James Gunton; James L Hare; Dariusz Korczyk; Fiona Kwok; Kaitlyn Lam; David Russell; Hasib Sidiqi; Tim Sutton; Simon D J Gibbs; Peter Mollee; Liza Thomas

doi:10.1016/j.hlc.2023.11.027

2024 Australia-New Zealand Expert Consensus Statement on Cardiac Amyloidosis

Heart Lung Circ. 2024 Apr;33(4):420-442. doi: 10.1016/j.hlc.2023.11.027. Epub 2024 Apr 2.

Authors

Nicole K Bart¹, Diane Fatkin², James Gunton³, James L Hare⁴, Dariusz Korczyk⁵, Fiona Kwok⁶, Kaitlyn Lam⁷, David Russell⁸, Hasib Sidiqi⁹, Tim Sutton¹⁰, Simon D J Gibbs¹¹, Peter Mollee¹², Liza Thomas¹³

Affiliations

¹ Department of Cardiology, St Vincent's Hospital, Sydney; School of Clinical Medicine, Faculty of Health and Medicine, The University of New South Wales, Sydney, and The Victor Chang Cardiac Research Institute, Sydney, NSW, Australia. Electronic address: http://www.twitter.com/drnikkibart.
² Department of Cardiology, St Vincent's Hospital, Sydney; School of Clinical Medicine, Faculty of Health and Medicine, The University of New South Wales, Sydney, and The Victor Chang Cardiac Research Institute, Sydney, NSW, Australia.
³ Department of Cardiology, Flinders Medical Centre, Adelaide, SA, Australia.
⁴ Department of Cardiology, Alfred Health, Melbourne, and Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Vic, Australia.
⁵ Department of Cardiology, The Princess Alexandra Hospital, Brisbane, Qld, Australia.
⁶ Department of Haematology, Westmead Hospital, Sydney, NSW, Australia.
⁷ Department of Cardiology, Western Australia Advanced Heart Failure and Cardiac Transplant Service, Perth, WA, Australia.
⁸ Department of Cardiology, Royal Hobart Hospital, Hobart, Tas, Australia.
⁹ Department of Haematology, Fiona Stanley Hospital, Perth, WA, Australia.
¹⁰ Te Whatu Ora Counties Manukau, Auckland; and Department of Cardiology, Auckland, Aotearoa, New Zealand.
¹¹ Department of Haematology, Eastern Health; Epworth Freemasons; and Monash University, Melbourne, Vic, Australia.
¹² Queensland Amyloidosis Centre, The Princess Alexandra Hospital, Brisbane; and, School of Medicine, University of Queensland, Brisbane, Qld, Australia.
¹³ Department of Cardiology, Westmead Hospital, Sydney; Westmead Clinical School, University of Sydney, Sydney; and, South West Clinical School, University of New South Wales, Sydney, NSW, Australia. Electronic address: [email protected].

PMID: 38570258
DOI: 10.1016/j.hlc.2023.11.027

Abstract

Over the past 5 years, early diagnosis of and new treatments for cardiac amyloidosis (CA) have emerged that hold promise for early intervention. These include non-invasive diagnostic tests and disease modifying therapies. Recently, CA has been one of the first types of cardiomyopathy to be treated with gene editing techniques. Although these therapies are not yet widely available to patients in Australia and New Zealand, this may change in the near future. Given the rapid pace with which this field is evolving, it is important to view these advances within the Australian and New Zealand context. This Consensus Statement aims to update the Australian and New Zealand general physician and cardiologist with regards to the diagnosis, investigations, and management of CA.

Keywords: Amyloidosis; Cardiac; Genetics; Heart failure; Heart failure with preserved ejection fraction; Hereditary; Transthyretin.

MeSH terms

Amyloidosis* / diagnosis
Amyloidosis* / therapy
Australia
Cardiomyopathies* / diagnosis
Cardiomyopathies* / therapy
Consensus*
Humans
New Zealand